BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30449217)

  • 1. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
    Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
    Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-A population-based register-linkage study.
    Lesén E; Granfeldt D; Houchard A; Berthon A; Dinet J; Gabriel S; Björstad Å; Björholt I; Elf AK; Johanson V
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12983. PubMed ID: 30652364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.
    Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Gomez MJ; Del Olmo-García MI; Lorenzo I; Díaz JÁ; Canal N; De la Cruz G; Villabona C
    Clin Transl Oncol; 2021 Oct; 23(10):2046-2056. PubMed ID: 34109562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
    Kostiainen I; Karppinen N; Simonen P; Rosengård-Bärlund M; Lindén R; Tarkkanen M; Gordin D; Rapola J; Schalin-Jäntti C; Matikainen N
    Endocrine; 2022 Jun; 77(1):177-187. PubMed ID: 35536452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
    Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
    Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoid heart disease in patients with midgut neuroendocrine tumours.
    Delhomme C; Walter T; Arangalage D; Suc G; Hentic O; Cachier A; Alkhoder S; François L; Lombard-Bohas C; Iung B; Ruszniewski P; de Mestier L
    J Neuroendocrinol; 2023 Apr; 35(4):e13262. PubMed ID: 37005217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Diarrhea in Patients With Carcinoid Syndrome.
    Naraev BG; Halland M; Halperin DM; Purvis AJ; OʼDorisio TM; Halfdanarson TR
    Pancreas; 2019 Sep; 48(8):961-972. PubMed ID: 31425482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.
    Broder MS; Chang E; Romanus D; Cherepanov D; Neary MP
    World J Gastroenterol; 2016 Feb; 22(6):2118-25. PubMed ID: 26877616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection.
    Kimbrough CW; Beal EW; Dillhoff ME; Schmidt CR; Pawlik TM; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Crown A; Abbott DE; Fisher AV; Fields RC; Krasnick BA; Idrees K; Marincola-Smith P; Cho CS; Beems M; Maithel SK; Cloyd JM
    Surgery; 2019 Mar; 165(3):657-663. PubMed ID: 30377003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.
    Halperin DM; Huynh L; Beaumont JL; Cai B; Bhak RH; Narkhede S; Totev T; Duh MS; Neary MP; Cella D
    BMC Cancer; 2019 Mar; 19(1):274. PubMed ID: 30922252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database.
    Perrier M; Mouawad C; Gueguen D; Thomé B; Lapeyre-Mestre M; Walter T
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102177. PubMed ID: 37453678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center.
    Jalbert JJ; Casciano R; Meng J; Brais LK; Pulgar SJ; Berthon A; Dinet J; Kulke MH
    Oncologist; 2020 Apr; 25(4):e644-e650. PubMed ID: 31999024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct costs of carcinoid syndrome diarrhea among adults in the United States.
    Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
    World J Gastroenterol; 2019 Dec; 25(47):6857-6865. PubMed ID: 31885426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.
    Khan MS; Walter T; Buchanan-Hughes A; Worthington E; Keeber L; Feuilly M; Grande E
    World J Gastroenterol; 2020 Aug; 26(30):4537-4556. PubMed ID: 32874063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
    Pasricha G; Padhi P; Daboul N; Monga DK
    Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
    Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
    Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report.
    Gerson JN; Witteles RM; Chang DT; Beygui RE; Iagaru AH; Kunz PL
    Pancreas; 2017; 46(10):1381-1385. PubMed ID: 29040196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
    Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
    J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
    Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
    Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.